Immuno‐Packed T‐Cell‐Fusogenic Liposome Empowers Adoptive T Cell Therapy for Solid Tumor Treatment
Advanced Materials · 2026
DOI: 10.1002/adma.202510842 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, 2026. Verfasst von Chunxiong Zheng und 11 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Biomaterials and Translational Medicine, Center for Nanomedicine, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510…. Hauptthemen laut MEDLINE: Liposomes, T-Lymphocytes, Immunotherapy, Adoptive, Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Natural Science Foundation of Guangdong Province for Distinguished Young Scholar, Guangdong Basic and Applied Basic Research Foundation.
Abstract (Originalsprache)
Adoptive T cell therapy has achieved remarkable success in certain blood cancers, but its efficacy against solid tumors remains limited by multiple immunological challenges including inadequate tumor infiltration, tumor cell's immune tolerance, and immunosuppressive tumor microenvironment (TME). Herein, a one‐step cell engineering strategy is reported to enhance T cell therapy for solid tumors using an immuno‐packed T‐cell‐fusogenic liposome (IMPACTFUL). Through membrane fusion, IMPACTFUL simultaneously decorates therapeutic T cells with D PPA peptides on their surface and delivers interleukin‐12 mRNA‐loaded magnetic nanoparticle cores (MNP/IL‐12) into the cytoplasm. MNP/IL‐12 internalization grants T cells with effective tumor targeting under external magnet and TME reversion through IL‐12 expression. D PPA peptide presentation enables T cells to overcome tumor cells’ immune tolerance through PD‐L1 checkpoint blockade. In a murine solid tumor model, IMPACTFUL‐engineered T cells infiltrate tumors more effectively, resist exhaustion, and induce a more pro‐inflammatory TME, leading to significantly suppressed tumor growth compared to unmodified T cells. Together, IMPACTFUL can empower adoptive T cell therapy by endowing T cells with multiple complementary functions in a single step. This approach offers a versatile platform to improve the therapeutic outcomes of T cell therapies against solid tumors and can accelerate their translation to clinical settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Biomaterials and Translational Medicine, Center for Nanomedicine, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510630, China.
- School of Chemistry, South China Normal University, Guangzhou, 510006, China.
- Department of Pharmaceutical Sciences, University at Buffalo, The State University of New York, Buffalo, NY, 14214, USA.
- State Key Laboratory of Optoelectronic Materials and Technologies, Guangdong Province Key Laboratory of Display Material and Technology, School of Electronics and Information Technology, Sun Yat-sen University, Guangzho…
- Key Laboratory and Engineering Laboratory of Lymphatic Surgery Jilin Province, China-Japan Union Hospital of Jilin University, Changchun, 130033, China.
- Cell-Gene Therapy Center, Institute for Frontier Interdisciplinary Research in Health Sciences and Technology, Key Laboratory for Polymeric Composite and Functional Materials of Ministry of Education, Sun Yat-Sen Univer…
ORCID-Profile: Mingqiang Li
Förderung
- National Key Research and Development Program of China
- Natural Science Foundation of Guangdong Province for Distinguished Young Scholar
- Guangdong Basic and Applied Basic Research Foundation
- Science and Technology Program of Guangzhou
- China Primary Health Care Foundation
- Guangdong Provincial Pearl River Talents Program
- National Natural Science Foundation of China
- Basic and Applied Basic Research Foundation of Guangdong Province
Zitieren
APA
Zheng, C., Yi, K., Du, Y., Zhong, Q., Kong, H., Wang, H., Ju, E., Lao, Y. H., Xie, X., Yao, H., Tao, Y., & Li, M. (2026). Immuno‐Packed T‐Cell‐Fusogenic Liposome Empowers Adoptive T Cell Therapy for Solid Tumor Treatment. Advanced Materials. https://doi.org/10.1002/adma.202510842
Vancouver
Zheng C, Yi K, Du Y, Zhong Q, Kong H, Wang H, et al. Immuno‐Packed T‐Cell‐Fusogenic Liposome Empowers Adoptive T Cell Therapy for Solid Tumor Treatment. Advanced Materials. 2026. doi:10.1002/adma.202510842
BibTeX
@article{Zheng2026,
author = {Zheng, Chunxiong and Yi, Ke and Du, Yongkang and Zhong, Qingguo and Kong, Huimin and Wang, Haixia and Ju, Enguo and Lao, Yeh-Hsing and Xie, Xi and Yao, Haochen and Tao, Yu and Li, Mingqiang},
title = {Immuno‐Packed T‐Cell‐Fusogenic Liposome Empowers Adoptive T Cell Therapy for Solid Tumor Treatment},
journal = {Advanced Materials},
year = {2026},
doi = {10.1002/adma.202510842}
}
EUVIMED